Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $17.63.

FOLD has been the topic of several research analyst reports. Morgan Stanley cut their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. JPMorgan Chase & Co. raised their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. StockNews.com raised Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, November 16th. Cantor Fitzgerald increased their price target on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Finally, Guggenheim boosted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, November 7th.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,901 shares of the company's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the transaction, the chief executive officer now owns 886,654 shares of the company's stock, valued at $11,083,175. This represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 30,401 shares of company stock worth $352,038 over the last three months. 2.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FOLD. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics in the third quarter worth about $26,000. Hazlett Burt & Watson Inc. boosted its holdings in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,569 shares during the period. Blue Trust Inc. grew its stake in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI bought a new stake in Amicus Therapeutics during the 3rd quarter valued at $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Amicus Therapeutics during the third quarter worth $55,000.

Amicus Therapeutics Trading Up 1.5 %

FOLD traded up $0.15 during trading on Tuesday, reaching $9.87. 1,534,997 shares of the stock traded hands, compared to its average volume of 2,709,086. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The stock's 50-day moving average is $10.80 and its 200 day moving average is $10.59. Amicus Therapeutics has a 12 month low of $9.02 and a 12 month high of $14.57. The stock has a market capitalization of $2.95 billion, a PE ratio of -29.15 and a beta of 0.68.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.